Roles of nitric oxide,endothelin-1 and homocysteine for the auxiliary diagnosis of coronary heart disease

doi:10.3969/j.issn.1673-8640.2018.04.009

Abstract

Abstract:

Objective To investigate the roles of serum nitric oxide（NO）,endothelin-1（ET-1） and homocysteine（Hcy） for the auxiliary diagnosis of coronary heart disease and their correlations. Methods Serum levels of NO,ET-1 and Hcy were determined in 264 patients with coronary heart disease and 90 healthy subjects（healthy control group）. The roles of NO,ET-1 and Hcy for the auxiliary diagnosis of coronary heart disease were evaluated by receiver operating characteristic（ROC） curve. The sensitivities and specificities of the 3 indices were determined according to optimal cut-off values. The risk factors,including age,sex,diabetes mellitus,hypertension,dyslipidemia,smoking and obesity,were used to correct the 3 indices. Unconditional Logistic regression analysis was used to assess the roles of NO,ET-1 and Hcy as risk factors for coronary heart disease and their correlations with coronary heart disease. Results The level of serum NO in coronary heart disease group was lower than that in healthy control group（P<0.001）,while the levels of ET-1 and Hcy were higher than those in healthy control group（P<0.001）. The areas under ROC curves of serum NO,ET-1 and Hcy for the auxiliary diagnosis of coronary heart disease were 0.723,0.742 and 0.718,respectively. The unconditional Logistic regression analysis showed that the odds ratios（OR） of NO,ET-1 and Hcy were 2.254,5.116 and 2.308,and 95% confidence intervals（CI） were 1.028-4.938,2.498-10.479 and 1.038-5.131,respectively. The indices having correlation intensities with coronary heart disease from high to low were ET-1,Hcy and NO. Conclusions Serum NO,ET-1 and Hcy play roles for the auxiliary diagnosis of coronary heart disease,and they are risk factors for coronary heart disease.

Key words: Nitric oxide, Endothelin-1, Homocysteine, Coronary heart disease, Risk factor

CLC Number:

R446.1

YANG Xuesong, SUN Fenyong, LI Zebing, WANG Jian. Roles of nitric oxide,endothelin-1 and homocysteine for the auxiliary diagnosis of coronary heart disease[J]. Laboratory Medicine, 2018, 33(4): 316-320.

Figures/Tables 5

References 15

[1]	中华人民共和国卫生部. WS319—2010 冠状动脉粥样硬化性心脏病诊断标准[S]. 北京:中国标准出版社,2010.
[2]	TOWNSEND N,NICHOLS M,SCARBOROUGH P,et al.Cardiovascular disease in Europe-epidemiological update 2015[J]. Eur Heart J,2015,36(40):2696-2705.
[3]	FINEGOLD J A,ASARIA P,FRANCIS D P.Mortality from ischaemic heart disease by country,region,and age:statistics from World Health Organisation and United Nations[J]. Int J Cardiol,2013,168(2):934-945.
[4]	陈灏珠,林果为,王吉耀. 实用内科学[M]. 14版. 北京:人民卫生出版社,2013: 1467-1495.
[5]	李媛媛,王琪. 同型半胱氨酸及血管内皮功能检测在脑梗死中的应用[J]. 检验医学,2014,29(10):1028-1030.
[6]	LEI J,VODOVOTZ Y,TZENG E,et al.Nitric oxide,a protective molecule in the cardiovascular system[J]. Nitric Oxide,2013,35:175-185.
[7]	KOLETTIS T M,BARTON M,LANGLEBEN D,et al.Endothelin in coronary artery disease and myocardial infarction[J]. Cardiol Rev,2013,21(5):249-256.
[8]	TODA N,OKAMURA T.Hyperhomocysteinemia impairs regional blood flow:involvements of endothelial and neuronal nitric oxide[J]. Pflugers Arch,2016,468(9):1517-1525.
[9]	GURDA D,HANDSCHUH L,KOTKOWIAK W,et al.Homocysteine thiolactone and N-homocysteinylated protein induce pro-atherogenic changes in gene expression in human vascular endothelial cells[J]. Amino Acids,2015,47(7):1319-1339.
[10]	JAKUBOWSKI H.The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease[J]. J Physiol Pharmacol,2008,59(Suppl 9):155-167.
[11]	JAKUBOWSKI H.Pathophysiological consequences of homocysteine excess[J]. J Nutr,2006,136(6 Suppl):1741S-1749S.
[12]	American Diabetes Association.8. Cardiovascular disease and risk management[J]. Diabetes Care,2016,39(Suppl 1):S60-S71.
[13]	利定建,孟丽琴,吴修宇,等. 3项指标与冠状动脉病变严重程度相关性研究[J]. 检验医学与临床,2015,12(9):1200-1202.
[14]	刘跃辉,张致丹,丁华,等. 高血压病患者颈动脉斑块与内皮细胞功能相关性的研究[J]. 中国卫生标准管理,2015,6(22):87-88.
[15]	刘永生,武国东,郑立文. 原发性高血压患者血一氧化氮及内皮素水平的研究[J]. 中国心血管病研究,2014,12(5):405-408.

组别	例数	年龄（岁）	性别		糖尿病 [例（%）]	高血压 [例（%）]
组别	例数	年龄（岁）	男[例（%）]	女[例（%）]	糖尿病 [例（%）]	高血压 [例（%）]
冠心病组	264	69.66±7.86	99（37.50）	165（62.50）	90（34.09）	119（45.08）
正常对照组	90	69.09±8.95	35（38.89）	55（61.11）	17（18.89）	22（24.44）
P值		0.356	0.815	0.815	0.007	0.001
组别	吸烟 [例（%）]	肥胖 [例（%）]	血脂异常 [例（%）]	NO （nmol/mL）	ET-1 （pg/mL）	Hcy （μmol/L）
冠心病组	97（36.74）	143（54.17）	87（32.96）	27.95（24.64~38.85）	8.57（5.00~11.09）	15.50（12.03~19.50）
正常对照组	14（15.56）	36（40.00）	19（21.11）	38.51（33.72~45.57）	5.44（3.33~6.96）	12.25（10.50~14.23）
P值	0.000	0.020	0.034	<0.001	<0.001	<0.001

组别	例数	年龄（岁）	性别		糖尿病 [例（%）]	高血压 [例（%）]
组别	例数	年龄（岁）	男[例（%）]	女[例（%）]	糖尿病 [例（%）]	高血压 [例（%）]
冠心病组	264	69.66±7.86	99（37.50）	165（62.50）	90（34.09）	119（45.08）
正常对照组	90	69.09±8.95	35（38.89）	55（61.11）	17（18.89）	22（24.44）
P值		0.356	0.815	0.815	0.007	0.001
组别	吸烟 [例（%）]	肥胖 [例（%）]	血脂异常 [例（%）]	NO （nmol/mL）	ET-1 （pg/mL）	Hcy （μmol/L）
冠心病组	97（36.74）	143（54.17）	87（32.96）	27.95（24.64~38.85）	8.57（5.00~11.09）	15.50（12.03~19.50）
正常对照组	14（15.56）	36（40.00）	19（21.11）	38.51（33.72~45.57）	5.44（3.33~6.96）	12.25（10.50~14.23）
P值	0.000	0.020	0.034	<0.001	<0.001	<0.001

项目	ROC曲线下面积（95%CI）	最佳临界值	敏感性（%）	特异性（%）	标准误
NO	0.723（0.666~0.779）	33.08 nmol/mL	63.2	81.8	0.029
ET-1	0.742（0.686~0.798）	7.31 pg/mL	65.4	85.2	0.029
Hcy	0.718（0.662~0.773）	14.55 μmol/L	60.9	83.0	0.028

项目	ROC曲线下面积（95%CI）	最佳临界值	敏感性（%）	特异性（%）	标准误
NO	0.723（0.666~0.779）	33.08 nmol/mL	63.2	81.8	0.029
ET-1	0.742（0.686~0.798）	7.31 pg/mL	65.4	85.2	0.029
Hcy	0.718（0.662~0.773）	14.55 μmol/L	60.9	83.0	0.028

项目	P值	OR值	95%CI
项目	P值	OR值	下限	上限
男性	0.668	0.898	0.548	1.741
年龄	0.319	1.015	0.985	1.046
糖尿病	0.011	2.136	1.187	3.841
高血压	0.000	2.837	1.631	4.937
血脂异常	0.023	1.955	1.098	3.483
吸烟	0.000	3.034	1.626	5.659
肥胖	0.020	1.787	1.095	2.918
NO	0.000	7.714	4.250	14.004
ET-1	0.000	10.911	5.749	20.709
Hcy	0.000	7.581	4.128	13.921